This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (497)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

The INCAS Trial

Julio S. G. Montaner, MD; Peter Reiss, MD; David Cooper, MD, DSc; Stefano Vella, MD; Marianne Harris, MD; Brian Conway, MD; Mark A. Wainberg, PhD; D. Smith, MD; Patrick Robinson, MD; David Hall, PhD; Maureen Myers, PhD; Joep M. A. Lange, MD, PhD; for the INCAS Study Group

JAMA. 1998;279:930-937.

Context.— Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease. However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.

Objective.— To compare the virologic effects of various combinations of nevirapine, didanosine, and zidovudine.

Design.— Double-blind, controlled, randomized trial.

Setting.— University-affiliated ambulatory research clinics in Italy, the Netherlands, Canada, and Australia (INCAS).

Patients.— Antiretroviral therapy–naive adults free of the acquired immunodeficiency syndrome with CD4 cell counts between 0.20 and 0.60x10⁹/L (200-600/µL).

Intervention.— Patients received zidovudine plus nevirapine (plus didanosine placebo), zidovudine plus didanosine (plus nevirapine placebo), or zidovudine plus didanosine plus nevirapine.

Main Outcome Measure.— Plasma HIV-1 RNA.

Results.— Of the 153 enrolled patients, 151 were evaluable. At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.05). The proportions of patients with plasma HIV-1 RNA levels below 20 copies per milliliter at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.001). Viral amplification was attempted in 59 patients at 6 months. Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively. Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy. Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=.08).

Conclusions.— Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied. Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.

From the Canadian HIV Trials Network, St Paul's Hospital/University of British Columbia, Vancouver (Drs Montaner, Harris, and Conway); National AIDS Therapy Evaluation Centre, Academic Medical Centre, Amsterdam, the Netherlands (Drs Reiss and Lange); the National Centre in HIV Epidemiology and Clinical Research (Dr Cooper) and Community HIV Research Network (Dr Smith), University of New South Wales, Sydney, Australia; Istituto Superiore di Sanita, Rome, Italy (Dr Vella); McGill University AIDS Centre/Jewish General Hospital, Montreal, Quebec (Dr Wainberg); and Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Conn (Drs Robinson, Hall, and Myers).

RELATED ARTICLE

HIV Treatment Strategies: Planning for the Long Term
Roy M. Gulick
JAMA. 1998;279(12):957-959.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach
Molto et al.
J Antimicrob Chemother 2008;62:784-792.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT | FULL TEXT  

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort
Maggiolo et al.
J Antimicrob Chemother 2007;59:569-572.
ABSTRACT | FULL TEXT  

Lessons learned from a paying antiretroviral therapy service in the public health sector at kamuzu central hospital, Malawi: 1-year experience.
Hosseinipour et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2006;5:103-108.
ABSTRACT  

Discordant immunological and virological responses to antiretroviral therapy
Schechter and Tuboi
J Antimicrob Chemother 2006;58:506-510.
ABSTRACT | FULL TEXT  

Sleep Disturbance and Depression as Barriers to Adherence
Phillips et al.
Clin Nurs Res 2005;14:273-293.
ABSTRACT  

Adherence to Antiretroviral Therapy: The Emerging Role of HIV Pharmacotherapy Specialists
Hardy
Journal of Pharmacy Practice 2005;18:247-257.
ABSTRACT  

Therapeutic Drug Monitoring: Role for a Pharmacist in Multidisciplinary Antiretroviral Management
Slish et al.
Journal of Pharmacy Practice 2005;18:310-321.
ABSTRACT  

A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients
Monie et al.
J. Virol. 2005;79:5185-5202.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders et al.
NEJM 2005;352:570-585.
ABSTRACT | FULL TEXT  

Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy-tert-Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1
Payen et al.
Antimicrob. Agents Chemother. 2005;49:525-535.
ABSTRACT | FULL TEXT  

A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides
Van Herrewege et al.
Antimicrob. Agents Chemother. 2004;48:3684-3689.
ABSTRACT | FULL TEXT  

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients
Torriani et al.
NEJM 2004;351:438-450.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-analytic Review
Crepaz et al.
JAMA 2004;292:224-236.
ABSTRACT | FULL TEXT  

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
Bangsberg et al.
J Antimicrob Chemother 2004;53:696-699.
ABSTRACT | FULL TEXT  

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials
Yazdanpanah et al.
BMJ 2004;328:249.
ABSTRACT | FULL TEXT  

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 x 109 cells/L
Wood et al.
ANN INTERN MED 2003;139:810-816.
ABSTRACT | FULL TEXT  

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
Wood et al.
CMAJ 2003;169:656-661.
ABSTRACT | FULL TEXT  

Factors Affecting Patient Adherence to Highly Active Antiretroviral Therapy
Escobar et al.
The Annals of Pharmacotherapy 2003;37:775-781.
ABSTRACT | FULL TEXT  

Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy
Frenkel et al.
J. Virol. 2003;77:5721-5730.
ABSTRACT | FULL TEXT  

Barriers to HAART Adherence Among Human Immunodeficiency Virus-Infected Adolescents
Murphy et al.
Arch Pediatr Adolesc Med 2003;157:249-255.
ABSTRACT | FULL TEXT  

In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months
Di Mascio et al.
J. Virol. 2003;77:2271-2275.
ABSTRACT | FULL TEXT  

Early Factors in Successful Anti-HIV Treatment
Piliero
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:10-20.
ABSTRACT  

HIV viral suppression in the era of antiretroviral therapy
Thaker and Snow
Postgrad. Med. J. 2003;79:36-42.
ABSTRACT | FULL TEXT  

Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness
Kuehne et al.
Arch Intern Med 2002;162:2545-2556.
ABSTRACT | FULL TEXT  

Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV
Dybul et al.
ANN INTERN MED 2002;137:381-433.
ABSTRACT | FULL TEXT  

Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons
Grant et al.
JAMA 2002;288:181-188.
ABSTRACT | FULL TEXT  

Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge
Trachtenberg and Sande
JAMA 2002;288:239-241.
FULL TEXT  

A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use
Manfredi et al.
J Antimicrob Chemother 2002;49:723-729.
ABSTRACT | FULL TEXT  

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy
Jordan et al.
BMJ 2002;324:757-757.
ABSTRACT | FULL TEXT  

Update on Didanosine
Cooper
J Int Assoc Physicians AIDS Care (Chic Ill) 2002;1:15-25.
ABSTRACT  

Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy
Hogg et al.
JAMA 2001;286:2568-2577.
ABSTRACT | FULL TEXT  

Initiating Antiretroviral Therapy During HIV Infection: Confusion and Clarity
Pomerantz
JAMA 2001;286:2597-2599.
FULL TEXT  

DRESS Syndrome Associated With Nevirapine Therapy
Claudio et al.
Arch Intern Med 2001;161:2501-2502.
FULL TEXT  

Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
Nieuwkerk et al.
Arch Intern Med 2001;161:1962-1968.
ABSTRACT | FULL TEXT  

Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection
Albrecht et al.
NEJM 2001;345:398-407.
ABSTRACT | FULL TEXT  

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
Bacheler et al.
J. Virol. 2001;75:4999-5008.
ABSTRACT | FULL TEXT  

Random effects models for HIV marker data: practical approaches with currently available software
Raab and Parpia
Stat Methods Med Res 2001;10:101-116.
ABSTRACT  

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg et al.
NEJM 2001;344:824-831.
ABSTRACT | FULL TEXT  

Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture
Archer et al.
J. Virol. 2000;74:8390-8401.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy
Bacheler et al.
Antimicrob. Agents Chemother. 2000;44:2475-2484.
ABSTRACT | FULL TEXT  

Gastrostomy Tube Insertion for Improvement of Adherence to Highly Active Antiretroviral Therapy in Pediatric Patients With Human Immunodeficiency Virus
Shingadia et al.
Pediatrics 2000;105:80e-80.
ABSTRACT | FULL TEXT  

Efavirenz in HIV Infection
Casado et al.
NEJM 2000;342:1290-1291.
FULL TEXT  

NNRTIs--a new class of drugs for HIV
Drake
J Antimicrob Chemother 2000;45:417-420.
FULL TEXT  

A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V
Hertogs et al.
Antimicrob. Agents Chemother. 2000;44:568-573.
ABSTRACT | FULL TEXT  

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
Regazzi et al.
J Antimicrob Chemother 2000;45:343-347.
ABSTRACT | FULL TEXT  

The Case for More Cautious, Patient-Focused Antiretroviral Therapy
Henry
ANN INTERN MED 2000;132:306-311.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society-USA Panel
Carpenter et al.
JAMA 2000;283:381-390.
ABSTRACT | FULL TEXT  

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski et al.
NEJM 1999;341:1865-1873.
ABSTRACT | FULL TEXT  

Choosing the Best Initial Therapy for HIV-1 Infection
Clumeck
NEJM 1999;341:1925-1926.
FULL TEXT  

HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed
Zolopa et al.
ANN INTERN MED 1999;131:813-821.
ABSTRACT | FULL TEXT  

Biotransformation of Nevirapine, a Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor, in Mice, Rats, Rabbits, Dogs, Monkeys, and Chimpanzees
Riska et al.
Drug Metab. Dispos. 1999;27:1434-1447.
ABSTRACT | FULL TEXT  

Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy
Dornadula et al.
JAMA 1999;282:1627-1632.
ABSTRACT | FULL TEXT  

Think HIV: Why Physicians Should Lower Their Threshold for HIV Testing
Freedberg and Samet
Arch Intern Med 1999;159:1994-2000.
FULL TEXT  

Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study
Moyer et al.
Clin. Chem. 1999;45:1465-1476.
ABSTRACT | FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points
Bucher et al.
JAMA 1999;282:771-778.
FULL TEXT  

Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice: Predictors of Virological Outcome
Valdez et al.
Arch Intern Med 1999;159:1771-1776.
ABSTRACT | FULL TEXT  

ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy
Para et al.
Antimicrob. Agents Chemother. 1999;43:1373-1378.
ABSTRACT | FULL TEXT  

Induction/Maintenance Treatment Regimens for HIV
Montaner
JAMA 1999;281:1680-1682.
FULL TEXT  

Nevirapine, Didanosine, and Zidovudine for Patients With HIV: The INCAS Trial
Clay et al.
JAMA 1999;281:130-131.
FULL TEXT  

Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride
Miller et al.
Antimicrob. Agents Chemother. 1998;42:3123-3129.
ABSTRACT | FULL TEXT  

Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays
Raboud et al.
J. Clin. Microbiol. 1998;36:3369-3371.
ABSTRACT | FULL TEXT  

Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection: 100-Week Follow-up
Gulick et al.
JAMA 1998;280:35-41.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel
Carpenter et al.
JAMA 1998;280:78-86.
ABSTRACT | FULL TEXT  

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg and Friedland
JAMA 1998;279:1977-1983.
ABSTRACT | FULL TEXT  

Three Drugs, No PI
AIDS Clin Care 1998;1998:6-6.
FULL TEXT  

Sustained HIV Suppression with Nevirapine Combination
JWatch Infect. Diseases 1998;1998:4-4.
FULL TEXT  

HIV Treatment Strategies: Planning for the Long Term
Gulick
JAMA 1998;279:957-959.
FULL TEXT